コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 egy: a cyclic phosphodiesterase that acts on adenosine diphosphate-ribose 1"-2" cyclic phosphate (App
2 isolated terminals, we tested 8-bromo-cyclic adenosine diphosphate ribose (8Br-cADPr), a competitive
3 ribosyltransferases catalyze the transfer of adenosine diphosphate ribose (ADP-ribose) from nicotinam
4 brane protein that converts NAD primarily to adenosine diphosphate ribose (ADPR) and a small amount o
7 where, involves the release of mitochondrial adenosine diphosphate ribose (ADPR) or nicotinamide aden
9 this strategy should be applicable to cyclic adenosine diphosphate ribose and nicotinic acid adenine
10 PM2 channels were activated by intracellular adenosine diphosphate-ribose and blocked by flufenamic a
11 f two potent Ca(2+) releasing agents: cyclic adenosine diphosphate ribose (cADPR) from nicotinamide a
12 of the calcium-mobilizing metabolite, cyclic adenosine diphosphate ribose (cADPR), from nicotinamide
17 sitol 1,4,5-trisphosphate (IP(3)) and cyclic adenosine diphosphate-ribose (cADPR) are second messenge
19 ng agents sphingosine-1-phosphate and cyclic adenosine diphosphate ribose exhibited weaker ABA-stimul
20 ial growth factor, 3-nitrotyrosine, and poly(adenosine diphosphate ribose) expression in lung tissue.
22 ROS), 3-nitrotyrosine (marker of RNS), poly(adenosine diphosphate-ribose) (PAR, marker of PARP activ
23 of caspase-2 and caspase-3, cleavage of poly(adenosine diphosphate-ribose) (poly(ADP-ribose)) polymer
24 accompanied by caspase-3 activation and poly-adenosine diphosphate ribose polymerase (PARP) cleavage
25 age during transplantation can activate poly-adenosine diphosphate ribose polymerase (PARP) resulting
26 on stress, a defect accentuated by poly-ADP (adenosine diphosphate) ribose polymerase inhibitors.
28 rial dysfunction, caspase cleavage, and poly adenosine diphosphate-ribose polymerase (PARP) degradati
29 by caspase-8, -9, and -3 and PARP (poly-ADP [adenosine diphosphate]-ribose polymerase) cleavage and d
30 NBC has rationalized clinical trials of poly(adenosine diphosphate ribose) polymerase (PARP) inhibito
32 ired IHHs displayed caspase activation, poly(adenosine diphosphate ribose) polymerase cleavage, and a
33 In cells deficient in the telomeric poly(adenosine diphosphate ribose) polymerase tankyrase 1, si
34 noblots demonstrated adaphostin induced poly(adenosine diphosphate-ribose) polymerase (PARP) cleavage
35 ected by caspases-3 and -8 cleavage and poly(adenosine diphosphate-ribose) polymerase (PARP) degradat
36 a rational target for therapy based on poly(adenosine diphosphate-ribose) polymerase (PARP) inhibiti
38 ated the effects of a novel ultrapotent poly(adenosine diphosphate-ribose) polymerase (PARP) inhibito
39 ding DNA fragmentation and cleavage of poly (adenosine diphosphate-ribose) polymerase (PARP), as well
40 ankyrins and to the catalytic domain of poly(adenosine diphosphate-ribose) polymerase (PARP), was ide
43 the human bax promoter and found that poly (adenosine diphosphate-ribose) polymerase 1 recruited the
45 C-alpha, phospho-PKC-beta1, and cleaved poly(adenosine diphosphate-ribose) polymerase in post-CP/Rep
46 HR) as measured by hypersensitivity to poly (adenosine diphosphate-ribose) polymerase inhibition and
47 high tidal volume ventilation plus the poly-(adenosine diphosphate-ribose) polymerase inhibitor 3-ami
48 e II prospective clinical trial of the poly-(adenosine diphosphate-ribose) polymerase inhibitor olapa
49 nstability in response to radiation and poly(adenosine diphosphate-ribose) polymerase inhibitors, com
51 ospho-PKC-alpha, phospho-PKC-beta1, and poly(adenosine diphosphate-ribose) polymerase were quantified
52 actor, caspase 3, caspase 8, caspase 9, poly(adenosine diphosphate-ribose) polymerase, B-cell lymphom
55 r 1) prevents it from inhibiting PARP1 [poly(adenosine diphosphate-ribose) polymerase], a critical DN
56 luorthanatrace (FTT) depicts activated poly (adenosine diphosphate-ribose)polymerase (PARP) expressio
58 ed forms of caspases-2 and -3, bax, and poly-adenosine diphosphate-ribose-polymerase (PARP) by Wester
59 ), enhanced cell death (caspase 3/7 and poly[adenosine diphosphate-ribose] polymerase activity, chrom
60 an essential substrate for sirtuins and poly(adenosine diphosphate-ribose) polymerases (PARPs), which
62 entification of an unexpected molecule, poly(adenosine diphosphate ribose), that may be implicated in
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。